NEW DELHI: Bharat Biotech International Ltd will lead a project sanctioned by the Council of Scientific and Industrial Research (CSIR) for developing human monoclonal antibodies as therapy for covid-19 infections, the company said in a release.
This programme—which brings together the National Centre for Cell Science (NCCS) in Pune, and Indian Institute of Technology-Indore and Gurgaon-based startup PredOmix Technologies apart from Bharat Biotech—is aimed at developing an alternate therapeutic regimen by generating effective and specific human monoclonal antibodies that are capable of neutralizing the novel coronavirus - SARS-CoV2. “The question is of how to treat those individuals who are already infected?